Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Post by jdstoxon Mar 12, 2019 1:46am
279 Views
Post# 29471569

Weather Report

Weather ReportI know people want me to make some big pronouncement about things that took place today. At the end of the day, I have only one thing on my mind, and that is the welfare of shareholders. Those who talk to me and who really read what I have to say here on Stockhouse, know that I will call it as I see it. I am not afraid to go to the dark side and discuss hard things.

With Bioasis, there is only one true thing and that is xB3. It shows every indication that it may cause a profound change in the treatment of innumerable neural disorders, and that suggests the potential for great value to shareholders.

I am not in the habit of discussing my conversations with company executives or directors. It's always sensitive stuff. However, I did have a lengthy discussion today with our new CEO, Deborah Rathjen.

I really liked what I heard. The drive is there. The understanding of what xB3 is, is there. It was apparent that new and different approaches for the advancement of xB3 are on the table.

Make no mistake, should I ever detect that the interests of shareholders are not paramount in the minds of directors and management, I will make those thoughts public. If differences in opinions arise between the Bioasis players, then that's just the way it is, but they must be resolved so that orderly progression towards well-conceived goals will take place.

I fully support the vision expressed to me today by Deborah Rathjen. I know a lot about Bioasis, but I was grateful to learn even more today.

When the weather changes, we put on different clothes and we go do what we have to do. The weather changed today, and I am dressed for it. 

You all can think what you want, but I will pull the covers up over my head tonight, and I will sleep in peace, not the with illusive assurance that we all will be rich, but with the sense that we are in good hands and that our hopes are alive and well.

All the best to my friend, Mark Day.

Godspeed to Deborah Rathjen and her team.

And to shareholders, layering is the order of the day. It could get hot.

jdstox

Bullboard Posts